Skip to content

A Hybrid Effectiveness-Implementation Trial of Urine Point-of-Care Assay to Increase PrEP Adherence Among Women in Kenya

A Hybrid Effectiveness-Implementation Trial of a Urine Point-of-Care Assay to Increase PrEP Adherence Among Women in Kenya

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07725679
Enrollment
400
Registered
2026-07-24
Start date
2027-02-01
Completion date
2031-08-01
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PrEP Adherence Monitoring

Brief summary

The goal of this randomized trial study is to learn if drug-level feedback counseling works to improve oral PrEP adherence in adolescent girls and young women. Researchers will compare urine TFV assay positivity between arms. All participants will attend visits on the same schedule, and receive the same SOC counseling for PrEP adherence. Participants in the intervention arm will additionally take POC urine TFV tests and receive drug-level feedback as part of that counseling.

Detailed description

This will be a randomized trial conducted in four public clinic facilities in Kiambu County. We will enroll 400 AGYW ages 15-29 who have been using oral PrEP for one month and will randomize them 1:1 to our DLFB intervention or standard-of-care (SOC). Enrolled AGYW will return for follow-up two months after enrollment and quarterly thereafter through 12 months. Intervention participants will receive DLFB counseling using our urine TFV assay at all visits. SOC arm participants will receive standard counseling; urine will be collected longitudinally but will be tested at study end. We will collect behavioral data via computer assisted self-interviewing (CASI) surveys. Our primary outcome will be the proportion of positive urine assays at each visit. We will compare urine TFV assay positivity between arms using a repeated measures mixed effects logistic regression model.

Interventions

DIAGNOSTIC_TESTPOC urine TFV test with DLFB

Women randomized to the intervention arm will take POC urine TFV tests and will receive drug level feedback (DLFB) alongside SOC counseling at each visit until exit.

Sponsors

University of Washington
Lead SponsorOTHER
National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 29 Years
Healthy volunteers
Yes

Inclusion criteria

* HIV uninfected * Received daily oral PrEP one month prior, with a negative result on a urine assay one-month post PrEP initiation * Currently attending or willing to attend one of the study clinics for PrEP refills * Interest in continuing on oral PrEP despite adherence challenges * No known sero-discordant relationships * Living in Kiambu County and not planning to relocate for the next year

Exclusion criteria

* Inadequate capacity to consent or complete planned study procedures * Do not speak English or Kiswahili * Test positive for HIV at screening * Concomitant participation in another PrEP adherence support study

Design outcomes

Primary

MeasureTime frameDescription
Urine TFV assayMonth 6 post-PrEP initiationTo determine the short-term adherence to PrEP between arms, we will look at the difference in the population proportions via a positive result on urine TFV assay over follow-up.

Contacts

CONTACTJennifer Morton
jfmorton@uw.edu
PRINCIPAL_INVESTIGATORJennnifer Velloza, PhD, MPH

University of Washington

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026